ArticleArthritis care & research2026
Major US Formulary Change Triggers, but Does Not Sustain, Increases in Biosimilar Adalimumab Prescribing.
Article in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early real-world utilization of ADA-adaz (Hyrimoz) in the United States: A retrospective claims-based descriptive study.Medicine · 2026Article
- Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D.JAMA network open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveCVS Caremark changed their national commercial formularies in 2024 to prefer adalimumab-adaz over originator. We assessed the formulary change's effect on biosimilar adalimumab prescribing in US community rheumatology practices.
methodsData come from Rheumatology Informatics System for Effectiveness, a registry of electronic health record data from participating community rheumatology practices nationwide. We used interrupted time series to analyze the effect of the CVS formulary change on the proportion of patients prescribed adalimumab-adaz or other adalimumab biosimilars each month between January 2023 and September 2024 stratified by payor and among new users.
resultsWe included 22,079 patients. Among those commercially insured, prescriptions for adalimumab-adaz went from nearly 0% to more than 25% following the CVS formulary change. In the next month, prescriptions for adalimumab-adaz dropped 12.3%. Prescriptions for other biosimilars increased slowly and linearly over the study period. Among patients with Medicare, we observed a similarly timed, but much smaller, increase in prescribing for both adalimumab-adaz and other biosimilar molecules without a large subsequent decrease. Among new users, prescriptions for adalimumab-adaz increased from 0% to 24% but was followed by a nearly 14% decrease in prescriptions in the first month after the formulary change. Other biosimilar prescriptions increased 0.6% per month throughout the period.
conclusionsAlthough biosimilar adalimumab prescriptions rose sharply after a major national formulary change, the increase was not sustained. These findings highlight that persistent barriers, including the nocebo effect and the administrative burden of switching, may continue to limit biosimilar adoption and contribute to the loss of substantial cost savings in the US market.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.